Cancer types
  • Digestive tract
Title of study
Influence of the intestinal microbiome on the outcome of treatment with preoperative chemoradiotherapy in patients with resectable oesophageal carcinoma
Version Number
Approval Date 
1, 3 October 2018
Short Title
Impac
Study site
Principle Investigator
Prof. Dr. H.W.M. van Laarhoven
Investigator Maastro
Dr J. Buijsen
Sponsor
AMC
Trial registry
Objectives 

In the PERFECT study (PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation) we investigate whether the composition of the microbiome is predictive for outcome of the treatment. In this observational study we investigate the specific contribution of the microbiome to the outcome of chemoradiation or atezolizumab

Primary Endpoint 

The faeces samples will be examined by 16S RNA sequencing for the composition of the intestinal microbiome. The extent to which these pathogens are present will be associated with (pathological) response to the chemoradiation

Secondary Endpoints